{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"aa6417fab88ea9c2c5e59b45a9cad1792a6c7be1b3ab7b91ae05cd361cd59921","attributes":{"feedName":"medwatch","feedSource":"medwatch","title":"Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease","description":"FDA has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic Hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure.","link":"http://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/hepatitis-c-medicines-mavyret-zepatier-and-vosevi-drug-safety-communication-due-rare-occurrence","publicationDate":"2019-08-29T14:06:53.000Z","state":"sent","affected":[],"allergens":[],"audience":["professionals"],"categories":["drugs"],"contaminants":[],"distribution":["AK","AL","AR","AZ","CA","CO","CT","DC","DE","FL","GA","HI","IA","ID","IL","IN","KS","KY","LA","MA","MD","ME","MI","MN","MO","MS","MT","NC","ND","NE","NH","NJ","NM","NV","NY","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VA","VT","WA","WI","WV","WY"],"risk":"possible","token":"5d9e68f98b079e002a25234e"}}}